Cargando…

Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery

There is no specific test for diagnosing neuromyelitis optica spectrum disorder (NMOSD), a disabling autoimmune disease of the central nervous system. Instead, diagnosis relies on ruling out other related disorders with overlapping clinical symptoms. An urgency for NMOSD biomarker discovery is under...

Descripción completa

Detalles Bibliográficos
Autores principales: Thoman, Maxton E., McKarns, Susan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570337/
https://www.ncbi.nlm.nih.gov/pubmed/32961928
http://dx.doi.org/10.3390/metabo10090374
_version_ 1783596925513105408
author Thoman, Maxton E.
McKarns, Susan C.
author_facet Thoman, Maxton E.
McKarns, Susan C.
author_sort Thoman, Maxton E.
collection PubMed
description There is no specific test for diagnosing neuromyelitis optica spectrum disorder (NMOSD), a disabling autoimmune disease of the central nervous system. Instead, diagnosis relies on ruling out other related disorders with overlapping clinical symptoms. An urgency for NMOSD biomarker discovery is underscored by adverse responses to treatment following misdiagnosis and poor prognosis following the delayed onset of treatment. Pathogenic autoantibiotics that target the water channel aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) contribute to NMOSD pathology. The importance of early diagnosis between AQP4-Ab(+) NMOSD, MOG-Ab(+) NMOSD, AQP4-Ab(−) MOG-Ab(−) NMOSD, and related disorders cannot be overemphasized. Here, we provide a comprehensive data collection and analysis of the currently known metabolomic perturbations and related proteomic outcomes of NMOSD. We highlight short chain fatty acids, lipoproteins, amino acids, and lactate as candidate diagnostic biomarkers. Although the application of metabolomic profiling to individual NMOSD patient care shows promise, more research is needed.
format Online
Article
Text
id pubmed-7570337
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75703372020-10-28 Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery Thoman, Maxton E. McKarns, Susan C. Metabolites Review There is no specific test for diagnosing neuromyelitis optica spectrum disorder (NMOSD), a disabling autoimmune disease of the central nervous system. Instead, diagnosis relies on ruling out other related disorders with overlapping clinical symptoms. An urgency for NMOSD biomarker discovery is underscored by adverse responses to treatment following misdiagnosis and poor prognosis following the delayed onset of treatment. Pathogenic autoantibiotics that target the water channel aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein (MOG) contribute to NMOSD pathology. The importance of early diagnosis between AQP4-Ab(+) NMOSD, MOG-Ab(+) NMOSD, AQP4-Ab(−) MOG-Ab(−) NMOSD, and related disorders cannot be overemphasized. Here, we provide a comprehensive data collection and analysis of the currently known metabolomic perturbations and related proteomic outcomes of NMOSD. We highlight short chain fatty acids, lipoproteins, amino acids, and lactate as candidate diagnostic biomarkers. Although the application of metabolomic profiling to individual NMOSD patient care shows promise, more research is needed. MDPI 2020-09-18 /pmc/articles/PMC7570337/ /pubmed/32961928 http://dx.doi.org/10.3390/metabo10090374 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Thoman, Maxton E.
McKarns, Susan C.
Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery
title Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery
title_full Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery
title_fullStr Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery
title_full_unstemmed Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery
title_short Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery
title_sort metabolomic profiling in neuromyelitis optica spectrum disorder biomarker discovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570337/
https://www.ncbi.nlm.nih.gov/pubmed/32961928
http://dx.doi.org/10.3390/metabo10090374
work_keys_str_mv AT thomanmaxtone metabolomicprofilinginneuromyelitisopticaspectrumdisorderbiomarkerdiscovery
AT mckarnssusanc metabolomicprofilinginneuromyelitisopticaspectrumdisorderbiomarkerdiscovery